ATP (Apple Tree Partners)的动态

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

Harness the power of OncolinesProfiler’s? sophisticated clustering analysis to map your compound’s IC50 fingerprint against the cellular activity of 213 anti-cancer therapeutics. Gain deep insights into your drug's biochemical action. Check out our capabilities and learn what we can do for you. https://ow.ly/X40x50QkHo2 #bioinformatics #comparativeprofiling

Imagine what you could do with 40% more cells after every isolation… Make it a reality with Akadeum's Alerion Microbubble Cell Separation System and our Human T Cell Leukopak Isolation Kit. Find out how Poseida Therapeutics is benefitting from the Alerion in this Case Study: https://hubs.li/Q02FVWDc0 #morecells #akadeum #celltherapy #cellisolation

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI.?Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

It's not too late to attend this webinar today - Pharmacogenomics: Transforming Patient Care

The Future of Exosome Based Therapeutics: Key Clinical Updates ZEO ScientifiX? invites you to a LIVE Webinar on The Future of Exosome Based Therapeutics with Dr. George Shapiro, MD https://lnkd.in/g5pnyr42

Did you miss it? Last month, we introduced our groundbreaking chemical modification search tool! If you are working in oligonucleotide therapeutics, and want to enhance your innovation capabilities, take a look at the link below and explore what this revolutionary tool can do for you! #oligonucleotide #RNA #chemicalmodification #innovation

Monitoring the trafficking of exosomes and EVs into target cells just got easier! Given the significance of exosomes and EVs for research, there is a growing need for reliable analytical methods to assess their uptake in live cells. Incucyte?? EV Uptake Assays offer a powerful tool in the development of new EV-based therapeutics. Have questions about your EV uptake? Discover solutions here: https://ow.ly/9HG250QEySV #exosomes #EVs #livecellanalysis #incucyte